| Naziv |
Akcije |
| Križić, Marija; Silovski, Tajana; Popović, Marina; Dedić Plavetić, Natalija
Bolesnice s HER2-pozitivnim rakom dojke i moždanim metastazama u tijeku prve linije liječenja: “Real-world” podaci iz KBC Zagreb // Liječnički vjesnik : glasilo Hrvatskog liječničkog zbora. Suplement, 145, 6. 2023. str. 64-65 |
|
| Radmilović Varga, Ljubica; Marić, Tihana; Katušić Bojanac, Ana; Horvatović, Kamelija; Popović, Marina; Kulić, Ana; Silovski, Tajana; Sirotković-Skerlev, Maja; Križić, Marija; Bulić, Krešimir et al.
301P Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls // Annals of oncology. Supplement, 34, 2. 2023. str. 304-304 doi: https://doi.org/10.1016/j.annonc.2023.09.497 |
|
| Kelečić, Ana; Čular, Katarina; Gudelj, Dora; Kukal Gjergaj, Iva; Toula, Lea; Kanceljak, Kristina; Lovrić, Marko; Križić, Marija; Popović, Marina; Dedić Plavetić, Natalija et al.
Utjecaj menopauzalnog statusa na ishod neoadjuvantnog liječenja ranog raka dojke // Liječnički vjesnik : glasilo Hrvatskog liječničkog zbora. Suplement, 145, 6. 2023. str. 50-51 |
|
| Čular, Katarina; Gudelj, Dora; Toula, Lea; Križić, Marija; Soče, Majana; Dedić Plavetić, Natalija; Popović, Marina; Silovski, Tajana
335P Real-world data: Correlation of radiological and pathologic complete response after neoadjuvant treatment of breast cancer // Annals of oncology. Supplement, 34, 2. 2023. str. 317-317 |
|
| Popović, Marina ; Silovski, Tajana ; Križić, Marija ; Dedić Plavetić, Natalija
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery? // International journal of molecular sciences, 24 (2023), 9; 8206, 1. doi: 10.3390/ijms24098206 |
|
| Križić, Marija ; Silovski, Tajana ; Popović, Marina ; Plavetić, Natalija Dedić
Real-world efficaccy of dual antiHER2 therapy in first line metastatic HER2- positive breast cancer and the possibility of prediction of long-term response // Cancer research (Baltimore) / Iacobuzio-Donahue, Christine A (ur.). 2023. doi: 10.1158/1538-7445.sabcs22-p4-01-39 |
|
| Dedic Plavetic, Natalija ; Čular, Katarina ; Križić, Marija ; Popovic, Marina ; Plestina, Stjepko ; Silovski, Tajana
Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin- dependent kinase 4/6 inhibitors (CDK4/6i): Real world data. // Journal of clinical oncology. 2023. doi: 10.1200/JCO.2023.41.16_suppl.e13078 |
|
| Popović, Marina
IL-17 u ranom invazivnom raku dojke / Dedić Plavetić, Natalija ; Kulić, Ana (mentor);
Zagreb, Medicinski fakultet u Zagrebu, . 2022 |
|
| Sermaxhaj, Faton ; Dedić Plavetić, Natalija ; Gozalan, Ugur ; Kulić, Ana ; Radmilović Varga, Ljubica ; Popović, Marina ; Sović, Slavica ; Mijatović, Davor ; Sermaxhaj, Besim ; Sopjani, Mentor
The role of interleukin‑7 serum level as biological marker in breast cancer: a cross‑sectional, observational, and analytical study // World journal of surgical oncology, 20 (2022), 1; 225, 9. doi: 10.1186/s12957-022-02646-7 |
|
| Gudelj, Dora ; Čular, Katarina ; Toula, Lea ; Vičić, Ivan ; Dedić Plavetić, Natalija ; Popović, Marina ; Križić, Marija ; Pleština, Stjepko ; Silovski, Tajana
Usporedba antraciklinskih i neantraciklinski protokola u neoadjuvantnom liječenju HER2 pozitivnog raka dojke u KBC Zagreb // Liječnički vjesnik : glasilo Hrvatskoga liječničkog zbora, 144 (2022), 4; 136-141 |
|
